Evaluation of effect of fluoxetine on the clinical prognosis in patients with anterior ischemic optic neuropathy (AION)

Phase 3

Recruiting

• Conditions: AION; Anterior ischemic optic neuropathy: is a condition in which the optic nerve is affected by ischemia at its anterior section (intraocular), AION has two types: arteritic and non arteritic types. arteritic type dominantly results from giant cell arteritis. The etiologies suggested for non arteritic type contains: diabetes mellitus, hypertension and obstructive sleep apnea. This research spends to non arteritic type of disease..

• Registration Number: IRCT20181109041596N1
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 January 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Iranian patients
Age over 18 years old
Patients with diagnosis of AION; non-arteritic type

Exclusion Criteria

Pregnancy before or during study
Past medical history of cataract, glaucoma ( open or close angle ) congenital eye disease such as cloboma and involvement with disease effecting the central visual field of patient
Patients with past medication history of using fluoxetine or other psychological medications including antidepressants
Patients suffering from psychological disease
Patients who use medications including :arthemeter? astemizol, cisapride, eliglustat, goserelin, isocarboxazide, artemether, leuprolide, linezolid, lumefantrine, methylene blue, phenelzine, pimozide, procarbazine, selegiline, thioridazine, tranylcypromine
Patients diagnosed with immunologic and collagen vascular disease
Patients with symptoms of or diagnosed with giant cell arteritis and positive CRP more than 3+ or ESR more than 40
Trauma or surgery history of eyes
Duration between involvement and interview more than 3 weeks
Patients without compliance of using fluoxetine or disagrement of patient to continue accompanying the study
Involvement by glaucoma
Involvement by cataract
Change in depression questionnaire score lower than 1 score in comparison to first and forth visit ( means the poor compliance of patient that has not used fluoxetine
Death of patient

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1)Visual acuity: visual acuity of each patient will measure by snelene chart. 2)Result of VEP test: both time( latency) and voltage parameters of VEP test will measure. Timepoint: 1)Visual acuity: in first visit and 6th month after initiation of treatment 2)VEP: in first visit and 6th month after initiation of treatment. Method of measurement: 1)Visual acuity: snelene chart 2)VEP test by means of VEP device.